(SLGL) Sol-Gel Technologies Ltd. PESTLE Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SLGL) Sol-Gel Technologies Ltd. Complete Analysis Pack
Plan Smarter. Present Sharper. Compete Stronger.
This Sol-Gel Technologies Ltd. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why those factors matter for strategy and investment. The page includes a real preview/sample of the report so you can assess style and depth; purchase the full version to receive the complete ready-to-use analysis.
Political factors
Israel-based headquarters in Ness Ziona
Sol-Gel Technologies Ltd.'s headquarters in Ness Ziona ties its clinical work, hiring, and partnerships to Israel's domestic policy and stability. That means shifts in government support for biotech, regulation, or security conditions can affect execution speed and investor confidence.
Being embedded in Israel's biotech ecosystem also helps access talent and collaborators, but it raises exposure to local political and budget priorities. If life sciences funding or approval support weakens, Sol-Gel Technologies' development momentum can slow quickly.
Life-science regulation in Israel and target markets
Sol-Gel Technologies Ltd. must clear Israel’s Ministry of Health plus key export regulators like the FDA and EMA before broad sales. The shift from Phase 3 data to marketing approval is where timeline risk sits, and the FDA approved 50 novel drugs in 2025, showing the bar stays high. Any filing delay can push revenue and launch timing back.
Geopolitical risk in the region
Israel’s security risk keeps logistics fragile, and Red Sea rerouting added roughly 10-14 days to Asia-Europe shipping in 2024-2025, which can delay trial supplies and raise costs. For Sol-Gel Technologies Ltd., that uncertainty can slow study sites, strain inventory, and reduce partner confidence. Backup suppliers and inventory buffers help protect development schedules.
Public healthcare priorities for dermatology
Skin disease is a major public health issue: the WHO says about 1.8 billion people live with skin conditions at any time, and acne, rosacea, and psoriasis keep dermatology on policy agendas. When governments push access to low-burden topical treatment, adoption can improve; for Sol-Gel Technologies Ltd., payer coverage and formulary status can still decide uptake and revenue speed.
1.8 billion people affected globally
Policy support favors topical medicines
Reimbursement drives market access
Strategic partnership with Perrigo
Sol-Gel Technologies Ltd. partnership with Perrigo ties its pipeline to a larger commercial platform, which can reduce market-entry friction and speed access across more countries. Because Perrigo sells in regulated consumer-health channels, the alliance is more exposed to trade rules, procurement policy, and cross-border supply issues than a solo launch.
Strategic partner strength matters here: Perrigo reported 2024 net sales of about $4.4 billion, so Sol-Gel Technologies Ltd. can benefit from a wider sales base and lower political risk if policy shifts hit one market. The trade-off is dependence on partner execution and any changes in import rules, tariffs, or healthcare channel policy.
- Broader commercial reach
- Lower entry friction
- Policy and trade exposure
- Partner execution risk
Sol-Gel’s Growth Hinges on Israel Risk and Perrigo Reach
Sol-Gel Technologies Ltd. is exposed to Israeli policy, security, and health-regulator risk, so any shift in Ministry of Health support or wartime logistics can delay trials and approvals. The FDA approved 50 novel drugs in 2025, showing the bar stays high.
Its Perrigo tie-up helps market reach, but also adds trade, import, and channel-policy risk. Perrigo reported about $4.4 billion in 2024 net sales.
| Factor | Latest data |
|---|---|
| FDA novel drug approvals | 50 in 2025 |
| Perrigo net sales | $4.4 billion in 2024 |
What is included in the product
Detailed Word Document
Examines how Political, Economic, Social, Technological, Environmental, and Legal forces shape Sol-Gel Technologies Ltd.’s risks and opportunities.
Customizable Excel Spreadsheet
A concise Sol-Gel Technologies Ltd. PESTLE snapshot that quickly surfaces external risks and opportunities for easier planning.
Reference Sources
Provides a concise, traceable bibliography of industry reports, government datasets, and benchmarks to validate Sol-Gel Technologies Ltd.’s market, pricing, and competitive claims.
Economic factors
Clinical-stage business model
Sol-Gel Technologies Ltd. remains a clinical-stage story, so near-term revenue visibility is weak and cash burn matters more than sales. Value is tied to Phase 3 readouts and FDA approval, and biotech approval odds from first-in-human to market are often under 10%. That creates a high-risk, high-upside economic profile.
Two Phase III assets
Sol-Gel Technologies Ltd.'s Twyneo and Epsolay both completed Phase III, and that late-stage data can lift valuation and improve partnering terms. The two assets also moved into U.S. commercialization after FDA approvals in 2021 and 2022, but execution risk stays high because sales depend on reimbursement, adoption, and launch strength. In a small-cap name, even one approved product can move revenue fast, yet weak uptake can still pressure cash burn.
Lower-cost topical delivery model
Sol-Gel Technologies Ltd. benefits from a lower-cost topical model because creams are easier to use than systemic drugs and can cut monitoring needs. Once-daily dosing helps adherence; in chronic dermatology, adherence often falls near 50%, so simpler use can lift sales appeal. Topical therapy also fits a large market, with psoriasis alone affecting about 125 million people worldwide.
Generic dermatology pipeline
Sol-Gel Technologies Ltd. uses generic topical dermatology to widen revenue beyond proprietary assets. In dermatology, generics can cut development time and cost because they rely on known active ingredients and bioequivalence, not new molecular discovery.
This matters for cash flow: 2025 U.S. prescription drug spending was about $435 billion, and generics filled most prescriptions at far lower prices, so even modest share can support steadier sales with lower R&D risk than novel drugs.
- Diversifies income
- Shorter launch cycle
- Lower scientific risk
Capital intensity of R&D
Capital intensity is high for Sol-Gel Technologies Ltd. because clinical trials, formulation work, and FDA filings need steady cash before sales start. In biopharma, a Phase 3 program can cost $20 million to $60 million, so late-stage work can quickly raise funding pressure. That makes partner-funded development and shared trial costs economically important.
- Trials and filings need ongoing cash
- Late stage raises burn before sales
- Partner support lowers funding risk
Sol-Gel’s 2025 Cash Burn Hinges on Twyneo, Epsolay Uptake
Sol-Gel Technologies Ltd. faces a tight cash profile in 2025/2026 because revenue still depends on Twyneo and Epsolay uptake, not steady product scale. Late-stage and commercial execution can move value fast, but weak reimbursement or slow adoption can keep burn high. Its generic topical line helps diversify income with lower R&D risk.
| Metric | 2025/2026 | Why it matters |
|---|---|---|
| U.S. prescription drug spend | $435B | Large market, but pricing pressure is high |
| Biotech approval odds | <10% | Raises economic risk for pipeline assets |
| Phase 3 cost | $20M-$60M | Funding pressure stays high before sales |
Preview Before You Purchase
Sol-Gel Technologies Ltd. PESTLE Analysis
The preview shown here is the exact Sol-Gel Technologies Ltd. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use with no placeholders or surprises.
Sociological factors
High prevalence of acne and rosacea
Acne vulgaris affects up to 85% of people ages 12 to 24, and rosacea impacts about 5% of adults worldwide. Sol-Gel Technologies Ltd.'s lead dermatology products target these two high-volume conditions, so broad patient prevalence can support recurring demand if approvals and uptake hold. In a market this large, even small penetration can translate into meaningful sales.
Demand for once-daily convenience
Sol-Gel Technologies Ltd.’s Twyneo and Epsolay are both once-daily products, and that matters because chronic dermatology patients often stick better to simpler regimens. In acne and rosacea care, convenience is a clear patient preference, so once-daily dosing can help real-world adherence and support repeat use.
Non-antibiotic treatment preference
Twyneo’s non-antibiotic profile fits a market more focused on antibiotic stewardship, as the WHO says antimicrobial resistance caused 1.27 million deaths in 2019. Patients and prescribers may prefer acne options that avoid antibiotic exposure and the resistance risk it brings. That can support uptake in acne care where long-term use is common.
Quality-of-life impact of skin disease
Skin disease can cut confidence and social contact; the WHO says skin conditions affect about 1.8 billion people at any time, and acne alone affects up to 85% of adolescents. That makes symptom control more than cosmetic: less redness, itching, and flares can improve daily comfort fast. Sol-Gel Technologies Ltd.'s topical pipeline can therefore create clear social value, not just clinical benefit.
About 1.8 billion people are affected worldwide.
Acne impacts up to 85% of teens.
Topicals can lift comfort and confidence.
Chronic care expectations
Psoriasis affects about 125 million people worldwide, and rosacea impacts up to 5% of adults, so Sol-Gel Technologies Ltd. addresses chronic care, not one-off use. Patients need treatments that fit daily routines, which supports demand for durable, simple-to-apply gels and creams. This favors repeat use and steady adherence in long-term management.
- Chronic skin diseases need routine use
- Easy-use formats improve adherence
- Repeat demand supports durable products
High-Need Skin Care, High-Value Market
Sol-Gel Technologies Ltd. sells into high-prevalence skin diseases: acne affects up to 85% of ages 12 to 24, and rosacea hits about 5% of adults. Because these conditions can hurt confidence and social life, effective topical care has real social value, not just medical value.
Once-daily, non-antibiotic products fit patient preference for simple routines and stewardship-friendly treatment.
That can support adherence, repeat use, and uptake in chronic dermatology care.
| Factor | Data |
|---|---|
| Acne prevalence | Up to 85% |
| Rosacea prevalence | About 5% |
| Skin disease burden | 1.8 billion people |
Technological factors
Proprietary microencapsulation platform
Sol-Gel Technologies Ltd.'s proprietary microencapsulation platform is the core of its topical drug design model, helping it control release, stability, and skin delivery. That differentiation can widen the pipeline and strengthen IP value, which matters for a small-cap company that reported $6.0 million in cash and cash equivalents at June 30, 2025. If the platform keeps producing new dermatology candidates, it can improve the odds of licensing and deal value.
Once-daily topical formulation design
Sol-Gel Technologies Ltd. builds skin-applied medicines, and once-daily creams fit that model because they cut use from 2 doses to 1, a 50% drop in daily handling. That can help adherence, since simpler regimens tend to be used more consistently. Formulation science is the core risk and edge here: drug delivery, skin feel, and stability can make or break product performance.
Phase III completion for Twyneo and Epsolay
Sol-Gel Technologies Ltd.'s two lead products, Twyneo and Epsolay, have both completed Phase III trials, which puts them far ahead of earlier-stage assets. That matters because Phase III success means the platform has moved beyond concept validation and into late-stage, regulatory-ready development. With 2 flagship programs already through this hurdle, Sol-Gel Technologies Ltd. shows a more mature technology base and lower clinical execution risk.
Early-stage expansion programs
Sol-Gel Technologies Ltd. is using early-stage expansion to spread technology risk across four dermatology programs: SGT-210 in Phase I, plus erlotinib, tapinarof, and roflumilast under investigation. That means one platform is being tested across multiple skin diseases, not just one lead asset. This setup can improve pipeline learning, but it also keeps clinical risk high until later-stage data arrive.
- 4 active programs in the early pipeline
- SGT-210 is in Phase I
- 3 more candidates are under investigation
- Platform is being tested across skin diseases
Generic topical development capability
Sol-Gel Technologies Ltd. shows that its know-how is not tied to novel molecules alone. With two FDA-approved topical acne drugs, EPSOLAY and TWYNEO, the Company has proved it can build and scale generic-style dermatology formulations too. That widens its technology base beyond one platform family and lowers dependence on a single product path.
- Two FDA-approved topical products
- Formulation skills beyond novel molecules
- Broader platform, lower concentration risk
Sol-Gel’s FDA-Backed Tech Edge, with $6M Cash on Hand
Sol-Gel Technologies Ltd.’s technology edge is its microencapsulation platform, which has already produced 2 FDA-approved products, TWYNEO and EPSOLAY, and supports once-daily topical dosing. That lowers use burden and can help adherence. The Company also had $6.0 million in cash and cash equivalents at June 30, 2025.
| Key tech factor | Latest data |
|---|---|
| Approved products | 2 FDA-approved |
| Early pipeline | 4 active programs |
| Cash at June 30, 2025 | $6.0 million |
Legal factors
Clinical trial compliance requirements
Sol-Gel Technologies Ltd. must run Phase I and Phase III studies under strict GCP rules, with regulators watching patient safety, trial conduct, and data integrity. Under ICH-GCP and FDA/EMA oversight, any protocol breach can trigger findings, hold-ups, or rejection of results, which can slow development by months or even stop a program.
Product approval pathways
Commercial launch for Sol-Gel Technologies Ltd. still hinges on separate approvals in each market, and dermatology drugs must meet quality, safety, and efficacy rules before sale. In the United States, FDA review is often 10 months for standard filings and 6 months for priority review, so timing can move revenue by quarters. That makes approval speed one of the biggest legal risks.
Intellectual property protection
Sol-Gel Technologies Ltd. relies on patents and related rights to protect its microencapsulation platform and product formulations, which sit at the core of its commercial value. Strong IP cuts copycat and generic pressure, while weak protection can quickly erode pricing power and margins. For a small specialty pharma company, even one lost product cycle can matter.
Partnership and licensing obligations
Sol-Gel Technologies Ltd.’s Perrigo alliance likely rests on detailed development and commercialization terms, including milestones, territorial rights, and revenue sharing. In a pipeline business, legal execution matters because missed obligations can delay filings, weaken cash flows, and limit value capture from licensed assets. If the contract is tight, Sol-Gel Technologies Ltd. protects upside and reduces dispute risk.
Define milestones clearly.
Track commercialization duties.
Protect revenue-share rights.
Generic competition and exclusivity rules
Sol-Gel Technologies Ltd. competes in a generic market where timing is legal strategy: first-filer 180-day exclusivity, 5-year new-chemical-entity exclusivity, and patent suits can block launch for up to 30 months under Hatch-Waxman. Bioequivalence proof is also strict, since FDA generic approvals still hinge on the same active ingredient, dose, and route.
- 180-day first-filer exclusivity can protect margins.
- 5-year exclusivity can delay generic entry.
- 30-month stays can shift launch timing.
- Patent cliffs decide who wins first sales.
Sol-Gel Faces FDA, Patent, and Exclusivity Risk
Sol-Gel Technologies Ltd. faces legal risk from FDA/EMA trial rules, since a protocol breach can delay or void data. U.S. approval timing matters too: standard review is 10 months, priority review 6 months.
Its value also depends on patents and license terms, because Hatch-Waxman can trigger a 30-month stay, and first-filer generic exclusivity can last 180 days.
| Legal factor | Key number |
|---|---|
| FDA standard review | 10 months |
| Priority review | 6 months |
| Hatch-Waxman stay | 30 months |
| First-filer exclusivity | 180 days |
Environmental factors
Pharmaceutical waste handling
Topical drug development and manufacturing create chemical, solvent, and packaging waste, so Sol-Gel Technologies Ltd. must manage hazardous streams under strict environmental rules. In the US, poor waste handling can trigger cleanup costs and penalties that can reach tens of thousands of dollars per violation per day. Tight segregation, treatment, and recycling cut contamination risk and lower operating risk.
Solvent and material use in formulation
Microencapsulation and cream production need tight control of raw materials, solvents, and process inputs. The IEA said the chemicals sector emitted about 1.5 Gt of CO2 in 2023, so solvent use and emissions face rising scrutiny. For Sol-Gel Technologies Ltd., better formulation efficiency can cut waste, lower VOC releases, and reduce disposal costs.
Energy use in R&D and manufacturing
Sol-Gel Technologies Ltd. uses energy in laboratory testing, stability studies, and production, so lower power use can improve both cost control and ESG performance. In Israel, where efficient operations are under growing scrutiny, energy per batch matters more as plants and labs face tighter operating expectations. Lower energy intensity also supports sustainability goals and can reduce exposure to rising utility costs.
Supply chain and logistics footprint
Sol-Gel Technologies Ltd. relies on regional and global supply chains to move drug substance, packaging, and finished products, so transport and warehousing add Scope 3 emissions and energy use. Partner-led distribution can lower or shift this footprint if logistics are consolidated, but it also reduces Sol-Gel Technologies Ltd.'s direct control over freight modes, storage, and return flows.
- Supply chain emissions rise with air and road freight.
- Warehousing adds power, cooling, and handling impacts.
- Partner distribution can shift the footprint profile.
Pressure for sustainable healthcare products
Healthcare buyers now weigh environmental impact more closely, and healthcare accounts for about 4.4% of global greenhouse-gas emissions. For Sol-Gel Technologies Ltd, dermatology products with simple, non-antibiotic profiles can fit sustainability-led buying criteria better than more complex therapies. That can support brand positioning where cleaner product stories matter.
- 4.4% of global emissions
- Simple profiles aid sustainability
- Brand story can improve
Sol-Gel’s Green Risk: Solvents, Waste, and Emissions
Environmental risk for Sol-Gel Technologies Ltd. centers on solvent waste, VOCs, energy use, and transport emissions. The chemicals sector emitted about 1.5 Gt of CO2 in 2023, and healthcare drives about 4.4% of global emissions, so cleaner formulations and tighter batch efficiency matter. Better segregation, recycling, and lower-power lab operations can cut disposal costs and ESG risk.
| Factor | Relevant data |
|---|---|
| Chemicals CO2 | 1.5 Gt in 2023 |
| Healthcare emissions | 4.4% global share |
| Key risk | Solvents, waste, freight |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.